RLAY · ISSUER CIK 1812364
Relay Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 5 Relay Therapeutics, Inc. insiders reported $0.00 of open-market purchases and $120.4M of sales on SEC Form 4.
↗5 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 8 of 9 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$120.4MInsider selling
−$120.4MNet open-market
Oct 8, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 8, 202617:29 | Oct 7, 2026 | RLAY | President and CEO, Director | S · Sell10b5-1 | $18.10 | −48,199 | 471,301 | -9% | −$872K | ||
| Oct 8, 202617:29 | Oct 6, 2026 | RLAY | Chief Financial Officer | S · Sell10b5-1 | $18.59 | −17,717 | 105,134 | -14% | −$329K | ||
| Sep 9, 202616:17 | Sep 8, 2026 | RLAY | President, R&D | S · Sell10b5-1 | $18.97 | −8,530 | 399,130 | -2% | −$162K | ||
| Sep 9, 202616:15 | Sep 8, 2026 | RLAY | Chief Financial Officer | S · Sell10b5-1 | $18.94 | −17,717 | 122,851 | -13% | −$336K | ||
| Sep 9, 202616:12 | Sep 8, 2026 | RLAY | President and CEO, Director | S · Sell10b5-1 | $18.94 | −48,199 | 519,500 | -8% | −$913K | ||
| Aug 28, 202616:43 | Aug 26, 2026 | RLAY | See remarks | S · Sell10b5-1 | $20.03 | −4,508 | 223,657 | -2% | −$90K | ||
| Aug 28, 202609:01 | Aug 25, 2026 | RLAY | 10% Owner · +2 joint | S · Sell | $19.40 | −6,000,000 | 21,904,963 | -22% | −$116.4M | ||
| Aug 18, 202616:17 | Aug 17, 2026 | RLAY | President and CEO, Director | S · Sell10b5-1 | $20.33 | −48,199 | 567,699 | -8% | −$980K | ||
| Aug 18, 202616:16 | Aug 14, 2026 | RLAY | Chief Financial Officer | S · Sell10b5-1 | $19.74 | −17,717 | 140,568 | -11% | −$350K |